A phase 3b, randomized, open-label study of the safety and efficacy of Dolutegravir/Abacavir/Lamivudine once daily compared to Atazanavir and Ritonavir plus Tenofovir/Emtricitabine once daily in HIV-1 infected antiretroviral therapy naïve women

This study is designed to demonstrate the non-inferior antiviral activity of DTG/ABC/3TC fixed dose combination (FDC) once daily (OD) compared to atazanavir plus ritonavir (ATV+RTV) and tenofovir disoproxil fumarate/emtricitabine fixed dose combination (TDF/FTC FDC) OD in HIV-1 infected, ART-naïve women over 48 weeks. This study will also characterize the safety and tolerability of DTG/ABC/3TC FDC compared to ATV+RTV+TDF/FTC FDC.